TY - JOUR
T1 - Hematologic malignancies following immune checkpoint inhibition for solid tumors
AU - van Eijs, Mick J.M.
AU - van der Wagen, Lotte E.
AU - Mous, Rogier
AU - Leguit, Roos J.
AU - van de Corput, Lisette
AU - van Lindert, Anne S.R.
AU - Suelmann, Britt B.M.
AU - Kamphuis, Anna M.
AU - Nierkens, Stefan
AU - Suijkerbuijk, Karijn P.M.
N1 - Funding Information:
We thank the Central Diagnostic Laboratory and Department of pathology for generously conducting and providing baseline molecular and cytogenetic analyses.
Publisher Copyright:
© 2022, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.
AB - Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.
KW - Case series
KW - Immune checkpoint inhibitor
KW - Leukemia
KW - Myeloid neoplasms
KW - Second primary cancer
UR - http://www.scopus.com/inward/record.url?scp=85131682357&partnerID=8YFLogxK
U2 - 10.1007/s00262-022-03230-4
DO - 10.1007/s00262-022-03230-4
M3 - Article
C2 - 35691988
SN - 0340-7004
VL - 72
SP - 249
EP - 255
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 1
ER -